Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.63 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.63 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.63 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.63 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.63 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.63 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.63 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.63 |
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.60 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.60 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.60 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.60 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.60 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.60 |
| ▸ | TTR known ✓ | P02766 | 1/20 | 0.59 |
| ▸ | NR3C1 known ✓ | P04150 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68386 | 0.98 | TAAR1 (1.00) | TAAR1LMNAGLATSHRMAPK1 | |
| SCHEMBL29365033 | 0.98 | TAAR1 (1.00) | TAAR1LMNAGLATSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL15845572 | 0.95 | TAAR1 (0.93) | TAAR1LMNAGLATSHRMAPK1 | |
| Dopamine SCHEMBL27902229 | 0.93 | TAAR1 (0.90) | TAAR1LMNAGLATSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL16799321 | 0.91 | TAAR1 (0.84) | TAAR1LMNAGLATSHRMAPK1 | |
| SCHEMBL28994052 | 0.91 | TSHR (0.90) | TAAR1LMNAGLATSHRMAPK1 | |
| Sulfuric Acid SCHEMBL17157294 | 0.90 | TAAR1 (0.84) | TAAR1LMNAGLATSHRMAPK1 | |
| SCHEMBL11856815 | 0.89 | TSHR (0.83) | TAAR1LMNAGLATSHRMAPK1 | |
| SCHEMBL17780116 | 0.88 | PTPN1 (0.82) | TAAR1LMNAGLATSHRMAPK1 | |
| SCHEMBL29604390 | 0.88 | PTPN1 (0.82) | TAAR1LMNAGLATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276107-A1 | HYDROGEL SYSTEMS AND METHODS FOR TREATING FISTULA AND OTHER INDICATIONS | TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION (US) | 2025-09-04 | — | — | US | claimed |
| CN-119565216-A | Solid-phase microextraction probe and preparation method and application thereof | 北京生命科技研究院有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-114460188-A | Kit for detecting human plasma catecholamine intermediate metabolite and testing method | 上海睿质科技有限公司 | 2022-05-10 | — | — | CN | claimed |
| CN-113416221-B | Total synthesis method of natural product phenanthrene alkaloid glycoside compound H4 | 江西中医药大学 | 2022-03-11 | — | — | CN | claimed |
| CN-113416221-A | Total synthesis method of natural product phenanthrene alkaloid glycoside compound H4 | 江西中医药大学 | 2021-09-21 | — | — | CN | claimed |
| US-8697898-B2 | Medical application of lipid derivatives of dopamine and the methods of their production | Instytut Medycyny Doswiadczalnej i Klinicznej im. M. Mossakowskiego PAN (PL) | 2014-04-15 | — | — | US | claimed |
| US-20130131361-A1 | NOVEL MEDICAL APPLICATION OF LIPID DERIVATIVES OF DOPAMINE AND THE METHODS OF THEIR PRODUCTION | Uniwersytet Warszawski, Wydzial Chemii (PL) | 2013-05-23 | — | — | US | claimed |
| US-20110224335-A1 | INK COMPOSITION AND METHOD OF FABRICATING LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | KIM SUNG-HEE | 2011-09-15 | — | — | US | claimed |
| EP-2324824-A2 | Medical application of lipid derivatives of dopamine | Instytut Medycyny Doswiadczalnej I Klinicznej (PL) | 2011-05-25 | — | — | EP | claimed |
| US-7935552-B2 | Ink composition and method of fabricating liquid crystal display device using the same | LG DISPLAY CO., LTD. (KR) | 2011-05-03 | — | — | US | claimed |
| CN-101949898-A | Method for detecting residual quantity of multiple alkaline drugs in animal derived food | SHANGHAI ANPEL SCIENT INSTR CO LTD | 2011-01-19 | — | — | CN | claimed |
| US-20100120181-A1 | INK COMPOSITION AND METHOD OF FABRICATING LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | LG DISPLAY CO., LTD. (KR) | 2010-05-13 | — | — | US | claimed |
| CN-122029157-A | Bilobalide derivatives for the treatment of neurological diseases and cancers | 香港中文大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | ENANTA PHARM INC (US) | 2025-12-11 | — | — | US | disclosed |
| CN-121027369-A | Kit and method for extracting catecholamines and metabolites thereof based on magnetic bead method and method for detecting catecholamines and metabolites thereof by LC-MS/MS | 北京豪思生物科技股份有限公司 | 2025-11-28 | — | — | CN | disclosed |
| US-20250276107-A1 | HYDROGEL SYSTEMS AND METHODS FOR TREATING FISTULA AND OTHER INDICATIONS | TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION (US) | 2025-09-04 | — | — | US | disclosed |
| US-4727079-A | Brain-specific dopaminergic activity involving dihydropyridine carboxamides, dihydroquinoline and isoquinoline carboxamides | UNIVERSITY OF FLORIDA (US) | 1988-02-23 | — | — | US | disclosed |
| US-4540564-A | DIHYDROPYRIDINE AND/OR PYRIDINIUM SALT REDOX CARRIER | UNIVERSITY OF FLORIDA (US) | 1985-09-10 | — | — | US | disclosed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | disclosed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | HSD17B1, HSD17B13, HSD17B3 | GLA 1137/4885ADRA2A 2518/4885DRD2 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.